| Not maintained DAS28 (ESR) <2.6 for 24 weeks (n = 146) | Maintained DAS28 (ESR) <2.6 for 24 weeks (n = 69) | |||
---|---|---|---|---|---|
Discontinued ADA (n = 51) | P b | Continued ADA (control) (n = 18) | P c | ||
Age, year | 61.1 ± 11.6 | 59.5 ± 11.2 | 0.3910 | 64.8 ± 10.4 | 0.0513 |
Gender, F:M | 127:19 | 40:11 | 0.1742 | 14:4 | 1.0000 |
Disease duration, year | 9.4 ± 10.3 | 7.1 ± 9.9 | 0.0356 | 6.7 ± 10.1 | 0.7375 |
RF, U/mL | 137.2 ± 248.5 | 109.0 ± 143.0 | 0.5539 | 283.5 ± 550.5 | 0.1400 |
TJC, 0 to 28 | 8.9 ± 6.7 | 8.1 ± 6.6 | 0.4014 | 7.6 ± 5.4 | 0.9727 |
SJC, 0 to 28 | 7.5 ± 5.5 | 6.4 ± 5.0 | 0.1770 | 6.7 ± 4.5 | 0.6214 |
PGA, 0 to 100 mm | 53.4 ± 24.8 | 39.0 ± 24.2 | 0.0008 | 47.8 ± 24.7 | 0.2185 |
EGA, 0 to 100 mm | 39.6 ± 22.7d | 31.5 ± 21.3 | 0.0398 | 34.7 ± 19.6g | 0.4636 |
CRP, mg/dl | 2.89 ± 4.07 | 2.27 ± 3.71 | 0.1460 | 1.61 ± 1.58 | 0.3817 |
ESR, mm/hour | 51.9 ± 32.4 | 43.2 ± 33.6 | 0.0574 | 45.6 ± 25.0 | 0.4318 |
DAS28 (ESR) | 5.57 ± 1.27 | 5.06 ± 1.26 | 0.0183 | 5.33 ± 1.25 | 0.3528 |
MMP-3, ng/ml | 313 ± 363 | 217 ± 339 | 0.0301 | 333 ± 233 | 0.0005 |
HAQ, 0 to 3 | 1.37 ± 0.77e | 0.91 ± 0.67 | 0.0003 | 1.27 ± 0.51h | 0.0295 |
MTX, mg/wf | 8.85 ± 3.11 | 8.96 ± 2.72 | 0.8937 | 9.61 ± 1.97 | 0.3480 |